[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623770":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":25,"id":59,"slug":25,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GLK-221 Ophthalmic Solution","EXPERIMENTAL","GLK-221 Ophthalmic Solution administered topically twice daily to both eyes",[13],"Drug: GLK-221 Ophthalmic Solution",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo Ophthalmic Solution administered topically twice daily to both eyes",[19],"Drug: Placebo Ophthalmic Solution",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","GLK-221 Ophthalmic Solution administered twice daily to both eyes",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo Ophthalmic Solution","Placebo Ophthalmic Solution administered twice daily to both eyes",[15],[31],{"name":32,"affiliation":5,"role":33},"Study Director, MD","STUDY_DIRECTOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Study Manager","CONTACT","949-739-8749","ClinicalResearch@Glaukos.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Glaukos Clinical Study Site","RECRUITING","Westerville","Ohio","43082","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-82.92907,40.12617,{"lat":53,"lon":52},[56],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":25},{"type":58,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100623770",false,"NCT07400952","Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus","Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus","Inclusion Criteria:\n\n* Be ≥ 18 and ≤ 55 years of age\n* Diagnosis of keratoconus in the study eye\n\nExclusion Criteria:\n\n* Pregnant, lactating or planning a pregnancy\n* Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial","ALL","18 Years","55 Years",{"count":69,"type":70},100,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.",[76],"Keratoconus",[76],"2026-02-03",{"date":80,"type":81},"2026-02-10","ACTUAL",{"date":83,"type":81},"2025-12-23",{"date":85,"type":70},"2027-04",{"name":5,"class":6},1]